Barbara Zellinger

Barbara Zellinger is a Researcher at the Institute of Pathology, actively engaged in multidisciplinary cancer research. Her work focuses on immunotherapy applications in lung cancer, particularly targeting Kirsten Rat Sarcoma Virus mutations and optimizing chemoradiotherapy protocols. She co-leads projects analyzing NSCLC treatment outcomes, radiation dosimetry, and biomarker discovery for cancer recurrence prediction.

Research interests include virus mutation mechanisms in oncology, radiation-induced toxicity, and translational biomarkers for personalized therapy. Her contributions span 25 peer-reviewed publications since 2007, with recent emphasis on NSCLC Stage III sub-cohort analyses and miRNA-driven breast cancer relapse studies. Projects include mutational analysis of BRCAness genes and miRNA regulation in breast cancer relapse mechanisms.

Key findings: Immunotherapy improves outcomes in K-ras-mutated NSCLC patients, and ESR/ATS DLCO thresholds correlate with radiation pneumonitis risk. Collaborations involve the Austrian Radio-Oncological Lung Cancer Study Association (ALLSTAR) and multi-institutional teams.

Her work has been highlighted in journals like Journal of Clinical Medicine and Cancers, with recent articles receiving citations and social media attention on platforms like Mendeley and Twitter.